Osteoporosis: Challenges and new opportunities for therapy

Current Opinion in Drug Discovery and Development

Volumn 5, Issue 4, 2002, Pages 477-486

  Rotella, David P ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Anabolic therapy; Calcium sensing receptor; Cathepsin K inhibitors; Osteoporosis; Parathyroid hormone; Prostanoids; Statins; Vitronectin antagonists

Indexed keywords

10,11 DIHYDRO 3 [3 (2 PYRIDINYLAMINO)PROPOXY] 5H DIBENZO[A,D]CYCLOHEPTENE 10 ACETIC ACID; 2 CHLORO 6 [3 [1,1 DIMETHYL 2 (2 NAPHTHYL)ETHYLAMINO] 2 HYDROXYPROPOXY]BENZONITRILE; 7 [3 HYDROXY 2 [3 HYDROXY 4 (3 METHOXYMETHYLPHENYL) 1 BUTENYL] 5 OXOCYCLOPENTYL] 5 THIAHEPTANOIC ACID METHYL ESTER; ALENDRONIC ACID; ATORVASTATIN; CALCIUM; CALCIUM SENSING RECEPTOR; CALCIUM SENSING RECEPTOR MODULATOR; CATHEPSIN K; CATHEPSIN K INHIBITOR; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PRAVASTATIN; PROSTANOID RECEPTOR; PROSTANOID RECEPTOR AGONIST; RISEDRONIC ACID; SB 223245; SB 290190; SB 412515; SB 468430; SB 468432; SIMVASTATIN; STATINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D; VITRONECTIN RECEPTOR; VITRONECTIN RECEPTOR ANTAGONIST; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE; PARATHYROID HORMONE (1 34); PARATHYROID HORMONE (1-34); PEPTIDE FRAGMENT;

BONE DENSITY; BONE MASS; BONE STRENGTH; CHRONIC DISEASE; CLINICAL TRIAL; DRUG FORMULATION; DRUG MECHANISM; DRUG STRUCTURE; FRACTURE; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; MOLECULAR MECHANICS; MORBIDITY; MORTALITY; NAUSEA; NONHUMAN; OSTEOPOROSIS; OSTEOSARCOMA; PHARMACODYNAMICS; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; DIET THERAPY; DRUG DELIVERY SYSTEM; METHODOLOGY; PATHOPHYSIOLOGY;

ANIMALS; CLINICAL TRIALS; DIPHOSPHONATES; DRUG DELIVERY SYSTEMS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMIDAZOLES; OSTEOPOROSIS; PARATHYROID HORMONE; PEPTIDE FRAGMENTS;

EID: 0036654299     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Graul Al, Sorbera LA, Prous JR: Osteoporosis. Drugs Today (2001) 37(10):703-727.
2. Sato M, Grese TA, Dodge JA, Bryant HU, Turner CH: Emerging therapies for the prevention or treatment of postmenopausal osteoporosis. J Med Chem (1999) 42(1):1-24.
3. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy: Osteoporosis: Prevention, diagnosis and therapy. J Am Med Assoc (2001) 285(6):785-795.
4. South-Paul JE: Osteoporosis: Part II. Non-pharmacologic and pharmacologic treatment. Am Fam Phys (2001) 63(6):1121-1128.
5. Rosen CJ, Bilezikian JP: Anabolic therapy for osteoporosis. J Clin Endocrinol Metab (2001) 86(3):957-964.
6. Tobias JH, Flanagan AM, Scutt AM: Novel therapeutic targets in osteoporosis. Exp Opin Ther Targets (2002) 6(1):41-56.
7. Rodan GA, Martin TJ: Therapeutic approaches to bone disease. Science (2000) 289(5484):1508-1514.
8. MacDonald BR, Gowen M: Emerging therapies in osteoporosis. Best Pract Res Clin Rheumatol (2001) 15(3):483-496.
9. Turner CH, Wang T, Hirano T, Burr DB, Hock JM, Hotchkiss CE, Brommage R, Jerome CP: In primates, treatment with PTH (1-34), LY33334 increases bone strength at trabecular bone sites without compromising the strength of cortical bone. J Bone Miner Res (1999) 14(Suppl 1):S414.
10. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R: Anabolic actions of parathyroid hormone on bone. Endocr Rev (1993) 14(6):690-709.
11. Neer RM, Amaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med (2001) 344(19):1434-1441. Clinical results with PTH 1-34 are presented and analyzed.
12. Cosman F, Nieves J, Woelfert L, Formica C, Gordon S, Shen V, Lindsay R: Parathyroid hormone added to established hormone therapy: Effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res (2001) 16(5):925-931.
13. Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezikian J, Lindsay R: Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study. J Bone Miner Res (2001) 16(10):1846-1853.
14. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ et al: Intravenous zolendronic acid in postmenopausal women with low bone mineral density. N Engl J Med (2002) 346(9):653-661. This paper describes the various dosing regimens and results of intermittent dosing with the bisphosphonate zolendronic acid.
15. Brown EM, MacLeod RJ: Extracellular calcium sensing and extracellular calcium signalling. Physiol Rev (2001) 81(1):239-297.
16. 2+ receptor antagonists that stimulate secretion of parathyroid hormone. J Pharmacol Exp Ther (2001) 299(1):323-331.
17. Gowen M, Stroup GB, Dodds RA, James IE, Vofta BJ, Smith BR, Bhatnagar PK, Lago AM, Callahan JF, DelMar EG, Miller MA, Nemeth EF, Fox J: Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J Clin Invest (2000) 105(11):1595-1604. The proof-of-principle that CaR antagonists are bone anabolic agents is demonstrated in vivo.
18. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G: Stimulation of bone formation in vitro and in rodents by statins. Science (1999) 286(5446):1946-1949. This paper presents in vitro and in vivo evidence suggesting that statins can act as anabolic agents on bone.
19. Garrett IR, Gutierrez G, Mundy GR: Statins and bone formation. Curr Pharm Design (2001) 7(8):715-736.
20. Edwards CJ, Hart DJ, Spector TD: Oral statins and increased bone-mineral density in postmenopausal women. Lancet (2000) 355(9222):2218-2219.
21. Wang PS, Solomon DH, Mogun H Avom J: HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. J Am Med Assoc (2000) 283(24):3211-3216.
22. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H: HMG-CoA reductase inhibitors and the risk of fractures. J Am Med Assoc (2000) 283(24):3205-3210.
23. Chan KA, Andrade SE, Boles M, Buist DS, Chase GA, Donahue JG, Goodman MJ, Gurwitz JH, LaCroix AZ, Platt R: Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet (2000) 355(9222):2185-2188.
24. Watanabe S, Fukumoto S, Takeuchi Y, Nakano T, Fujita T: Effects of one year treatment with statins on bone mass and metabolism. J Bone Miner Res (2000) 15(Suppl 1):S194.
25. Jee WS, Ma YF: The in vivo anabolic actions of prostaglandins in bone. Bone (1997) 21(4):297-304.
26. Coleman RA, Smith WL, Narumiya S: International Union of Pharmacology classification of prostanoid receptors: Properties, distribution and structures of the receptors and their subtypes. Pharmacol Rev (1994) 46(2):205-229.
27. Hartke JR, Lundy MW: Bone anabolic therapy with selective prostaglandin analogs. J Musculoskel Neuron Interact (2001) 2(1):25-31.
28. Sugimoto Y, Narumiya S, Ichikawa A: Distribution and function of prostanoid receptors: Studies from knockout mice. Prog Lipid Res (2000) 39(4):289-314.
29. 2 in rat bone marrow cultures is mediated via the EP4 receptor subtype. Am J Physiol (1999) 276(2 Pt 1):E376-E383.
30. 2. Mol Pharmacol (2001) 60(1):36-41.
31. Maruyama T, Asada M, Shiraishi T, Ishida A, Egashira H, Yoshida H, Maruyama T, Ohuchida S, Nakai H, Kondo K, Toda M: Design and synthesis of a highly selective EP4-receptor agonist. Part 1: 3,7-dithiaPG derivatives with high selectivity. Bioorg Med Chem Lett (2001) 11(15):2029-2031.
32. Maruyama T, Asada M, Shiraishi T, Sakata K, Seki A, Yoshida H, Shinagawa Y, Maruyama T, Ohuchida S, Nakai H, Kondo K, Toda M: Design and synthesis of a highly selective EP4-receptor agonist. Part 2: 5-thia and 9β-haloPG derivatives with improved stability. Bioorg Med Chem Lett (2001) 11(15):2033-2035.
33. 2.
34. 1 derivatives and identification of their ω chains. Bioorg Med Chem (2002) 10(4):975-988.
35. 1 derivatives with high selectivity. Bioorg Med Chem (2002) 10(4):989-1008.
36. 1 and 9β-halo derivatives with improved stability. Bioorg Med Chem (2002) 10(6):1743-1759.
37. 2α on the skeleton of osteopenic ovariectomized rats. Bone (1995) 17(6):549-554.
38. Soper DL, Milbank JBJ, Mieling GE, Dirr MJ, Kende AS, Cooper R, Jee WSS, Yao W, Chen JL, Bodman M, Lundy MW, De B, Stella ME, Ebetino FH, Wang Y, deLong MA, Wos JA: Synthesis and biological evaluation of prostaglandin-F alkylphosphinic acid derivatives as bone anabolic agents for the treatment of osteoporosis. J Med Chem (2001) 44(24):4157-4169.
39. Drake FH, Dodds RA, James IE, Connor JR, Debouck C, Richardson S, Lee-Rykaczewski E, Coleman L, Rieman D, Barthlow R, Hastings G, Gowen M: Cathepsin K, but not cathepsins B, L or S, is abundantly expressed in human osteoclasts. J Biol Chem (1996) 271(21):12511-12516.
40. Saftig P, Hunziger E, Wehmeyer O, Jones S, Boyde A, Rommerskirch W, Moritz JD, Schu P, von Figura K: Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin K-deficient mice. Proc Natl Acad Sci USA (1998) 95(23):13453-13458.
41. Gelb BD, Shi GP, Chapman HA, Desnick RJ: Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science (1996) 273(5279):1236-1238.
42. Woo JT, Yamaguchi K, Hayama T, Kobori T, Sigeizumi S, Sugimoto K, Kondo K, Tsuji T, Ohba Y, Tagami K, Sumitani K: Suppressive effect of N-(benzyloxycarbonyl)-L-phenylalanyl-L-tyrosinal on bone resorption in vitro and in vivo. Eur J Pharmacol (1996) 300(1-2):131-135.
43. Yasuma T, Oi S, Choh N, Nomura T, Furuyama N, Nishimura A, Fujisawa Y, Sohda T: Synthesis of peptide aldehyde derivatives as selective inhibitors of human cathepsin L and their inhibitory effect on bone resorption. J Med Chem (1998) 41(22):4301-4308.
44. James IE, Marquis RW, Blake SM, Hwang SM, Gress CJ, Ru Y, Zembryki D, Yamashita DS, McQueney MS, Tomaszek TA, Oh HJ, Gowen M, Veber DF, Lark MW: Potent and selective cathepsin L inhibitors do not inhibit human osteoclast resorption in vitro. J Biol Chem (2001) 276(15):11507-11511.
45. DesJarlais RL, Yamashita DS, Oh H-J, Uzinskas IN, Erhard KF, Allen AC, Haltiwanger RC, Zhao B, Smith WW, Abdel-Meguid SS, D'Alessio K, Janson CA, McQueney MS, Tomaszek TA, Levy MA, Veber DF: Use of X-ray co-crystal structures and molecular modeling to design potent and selective non-peptide inhibitors of cathepsin K. J Am Chem Soc (1998) 120(35):9114-9115.
46. Marquis RW, Ru Y, Zeng J, Trout RE, LoCastro SM, Gribble AD, Witherington J, Fenwick AE, Gamier B, Tomaszek T, Tew D, Hemling ME, Quinn CJ, Smith WW, Zhao B, McQueney MS, Janson CA, D'Alessio K, Veber DF: Cyclic ketone inhibitors of the cysteine protease cathepsin K. J Med Chem (2001) 44(5):725-736.
47. Marquis RW, Ru Y, LoCastro SM, Zeng J, Yamashita DS, Oh HJ, Erhard KF, Davis LD, Tomaszek TA, Tew D, Salyers K et al: Azepanone-based inhibitors of human and rat cathepsin K. J Med Chem (2001) 44(9):1380-1395. This paper describes the GlaxoSmithKline group's cathepsin K program and provides their latest results.
48. Stroup GB, Lark MW, Veber DF, Bhattacharyya A, Blake S, Dare LC, Erhard KF, Hoffman SJ, James IE, Marquis RW, Ru Y, Vasko-Moser JA, Smith BR, Tomaszek T, Gowen M: Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate. J Bone Miner Res (2001) 16(10):1739-1746.
49. Falgueyret JP, Oballa RM, Okamoto O, Wesolowski G, Aubin Y, Rydzewski RM, Prasit P, Riendeau D, Rodan SB, Percival MD: Novel non-peptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L. J Med Chem (2001) 44(1):94-104.
50. Clover J, Dodds RA, Gowen M: Integrin subunit expression by human osteoblasts and osteoclasts in situ and in culture. J Cell Sci (1992) 103(Pt 1):267-271.
51. Engleman VW, Nickols GA, Ross FP, Horton MA, Griggs DW, Settle SL, Ruminski PG, Teitelbaum SL: A peptidomimetic antagonist of the αvβ3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. J Clin Invest (1997) 99(9):2284-2292.
52. Miller WH, Bondinell WE, Cousins RD, Erhard KF, Jakas DR, Keenan RM, Ku TW, Newlander KA, Ross ST, Haltiwanger RC, Bradbeer J et al: Orally bioavailable non-peptide vitronectin receptor antagonists with efficacy in an osteoporosis model. Bioorg Med Chem Lett (1999) 9(13):1807-1812.
53. Lark MW, Stroup GB, Hwang SM, James IE, Rieman DJ, Drake FH, Bradbeer JN, Mathur A, Erhard KF, Newlander KA, Ross ST, Salyers KL, Smith BR, Miller WH, Huffman WF, Gowen M: Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB265123 for prevention of bone loss in osteoporosis. J Pharmacol Exp Ther (1999) 291(2):612-617.
54. Miller WH, Alberts DP, Bhatnagar PK, Bondinell WE, Callahan JF, Calvo RR, Cousins RD, Erhard KF, Heerding DA, Keenan RM, Kwon C et al: Discovery of orally active non-peptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic. J Med Chem (2000) 43(1):22-26. This paper describes detailed SAR information leading to the discovery of SB-265123.
55. Lark MW, Stroup GB, Dodds RA, Kapadia R, Hoffman SJ, Hwang SM, James IE, Lechowska B, Liang X, Rieman DJ, Salyers KL, Ward K, Smith BR, Miller WH, Huffman WF, Gowen M: Antagonism of the osteoclast vitronectin receptor with an orally active non-peptide inhibitor prevents cancellous bone loss in the ovariectomized rat. J Bone Miner Res (2001) 16(2):319-327.